Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Saposin C protects glucocerebrosidase against α-synuclein inhibition.

Yap TL, Gruschus JM, Velayati A, Sidransky E, Lee JC.

Biochemistry. 2013 Oct 15;52(41):7161-3. doi: 10.1021/bi401191v. Epub 2013 Oct 1.

2.

Dissociation of glucocerebrosidase dimer in solution by its co-factor, saposin C.

Gruschus JM, Jiang Z, Yap TL, Hill SA, Grishaev A, Piszczek G, Sidransky E, Lee JC.

Biochem Biophys Res Commun. 2015 Feb 20;457(4):561-6. doi: 10.1016/j.bbrc.2015.01.024. Epub 2015 Jan 17.

3.

Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases.

Yap TL, Gruschus JM, Velayati A, Westbroek W, Goldin E, Moaven N, Sidransky E, Lee JC.

J Biol Chem. 2011 Aug 12;286(32):28080-8. doi: 10.1074/jbc.M111.237859. Epub 2011 Jun 8.

4.

Structural features of membrane-bound glucocerebrosidase and α-synuclein probed by neutron reflectometry and fluorescence spectroscopy.

Yap TL, Jiang Z, Heinrich F, Gruschus JM, Pfefferkorn CM, Barros M, Curtis JE, Sidransky E, Lee JC.

J Biol Chem. 2015 Jan 9;290(2):744-54. doi: 10.1074/jbc.M114.610584. Epub 2014 Nov 26.

5.

Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells.

Ambrosi G, Ghezzi C, Zangaglia R, Levandis G, Pacchetti C, Blandini F.

Neurobiol Dis. 2015 Oct;82:235-42. doi: 10.1016/j.nbd.2015.06.008. Epub 2015 Jun 19.

PMID:
26094596
6.

Glucocerebrosidase and Parkinson disease: Recent advances.

Schapira AH.

Mol Cell Neurosci. 2015 May;66(Pt A):37-42. doi: 10.1016/j.mcn.2015.03.013. Epub 2015 Mar 20. Review.

7.

Loss of glucocerebrosidase 1 activity causes lysosomal dysfunction and α-synuclein aggregation.

Bae EJ, Yang NY, Lee C, Lee HJ, Kim S, Sardi SP, Lee SJ.

Exp Mol Med. 2015 Mar 27;47:e153. doi: 10.1038/emm.2014.128. Erratum in: Exp Mol Med. 2015;47:e188.

8.

Loss of β-glucocerebrosidase activity does not affect alpha-synuclein levels or lysosomal function in neuronal cells.

Dermentzaki G, Dimitriou E, Xilouri M, Michelakakis H, Stefanis L.

PLoS One. 2013 Apr 8;8(4):e60674. doi: 10.1371/journal.pone.0060674. Print 2013.

9.

Membrane-bound α-synuclein interacts with glucocerebrosidase and inhibits enzyme activity.

Yap TL, Velayati A, Sidransky E, Lee JC.

Mol Genet Metab. 2013 Jan;108(1):56-64. doi: 10.1016/j.ymgme.2012.11.010. Epub 2012 Nov 28.

10.

The N370S (Asn370-->Ser) mutation affects the capacity of glucosylceramidase to interact with anionic phospholipid-containing membranes and saposin C.

Salvioli R, Tatti M, Scarpa S, Moavero SM, Ciaffoni F, Felicetti F, Kaneski CR, Brady RO, Vaccaro AM.

Biochem J. 2005 Aug 15;390(Pt 1):95-103.

11.

Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains.

Gegg ME, Burke D, Heales SJ, Cooper JM, Hardy J, Wood NW, Schapira AH.

Ann Neurol. 2012 Sep;72(3):455-63. doi: 10.1002/ana.23614.

12.

Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.

Rocha EM, Smith GA, Park E, Cao H, Brown E, Hayes MA, Beagan J, McLean JR, Izen SC, Perez-Torres E, Hallett PJ, Isacson O.

Neurobiol Dis. 2015 Oct;82:495-503. doi: 10.1016/j.nbd.2015.09.009. Epub 2015 Sep 25.

13.

Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies.

Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, Sidransky E, Grabowski GA, Krainc D.

Cell. 2011 Jul 8;146(1):37-52. doi: 10.1016/j.cell.2011.06.001. Epub 2011 Jun 23.

14.

Saposin C mutations in Gaucher disease patients resulting in lysosomal lipid accumulation, saposin C deficiency, but normal prosaposin processing and sorting.

Vaccaro AM, Motta M, Tatti M, Scarpa S, Masuelli L, Bhat M, Vanier MT, Tylki-Szymanska A, Salvioli R.

Hum Mol Genet. 2010 Aug 1;19(15):2987-97. doi: 10.1093/hmg/ddq204. Epub 2010 May 19.

PMID:
20484222
15.

Glucocerebrosidase, a new player changing the old rules in Lewy body diseases.

Yang NY, Lee YN, Lee HJ, Kim YS, Lee SJ.

Biol Chem. 2013 Jul;394(7):807-18. doi: 10.1515/hsz-2012-0322. Review.

PMID:
23435096
16.

Glucocerebrosidase enzyme activity in GBA mutation Parkinson's disease.

Ortega RA, Torres PA, Swan M, Nichols W, Boschung S, Raymond D, Barrett MJ, Johannes BA, Severt L, Shanker V, Hunt AL, Bressman S, Pastores GM, Saunders-Pullman R.

J Clin Neurosci. 2016 Jun;28:185-6. doi: 10.1016/j.jocn.2015.12.004. Epub 2016 Feb 5.

17.

Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease.

Murphy KE, Gysbers AM, Abbott SK, Tayebi N, Kim WS, Sidransky E, Cooper A, Garner B, Halliday GM.

Brain. 2014 Mar;137(Pt 3):834-48. doi: 10.1093/brain/awt367. Epub 2014 Jan 28.

18.

Sustained Systemic Glucocerebrosidase Inhibition Induces Brain α-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice.

Rocha EM, Smith GA, Park E, Cao H, Graham AR, Brown E, McLean JR, Hayes MA, Beagan J, Izen SC, Perez-Torres E, Hallett PJ, Isacson O.

Antioxid Redox Signal. 2015 Aug 20;23(6):550-64. doi: 10.1089/ars.2015.6307. Epub 2015 Jul 29.

19.

Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and dementia with Lewy bodies.

Chiasserini D, Paciotti S, Eusebi P, Persichetti E, Tasegian A, Kurzawa-Akanbi M, Chinnery PF, Morris CM, Calabresi P, Parnetti L, Beccari T.

Mol Neurodegener. 2015 Mar 27;10:15. doi: 10.1186/s13024-015-0010-2.

20.

Emerging insights into the mechanistic link between α-synuclein and glucocerebrosidase in Parkinson's disease.

McGlinchey RP, Lee JC.

Biochem Soc Trans. 2013 Dec;41(6):1509-12. doi: 10.1042/BST20130158.

Supplemental Content

Support Center